Literature DB >> 2843087

Clinical isolate of Citrobacter freundii highly resistant to new quinolones.

H Aoyama1, K Fujimaki, K Sato, T Fujii, M Inoue, K Hirai, S Mitsuhashi.   

Abstract

About 30% of 150 recent clinical isolates of Citrobacter freundii were resistant to greater than or equal to 3.13 micrograms of norfloxacin and ofloxacin per ml. Study of one quinolone-resistant strain for which the norfloxacin MIC was 100 micrograms/ml suggested that resistance was associated with both an altered A subunit of DNA gyrase and reduction in drug uptake accompanied by a decrease in an outer membrane protein.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2843087      PMCID： PMC172307          DOI： 10.1128/AAC.32.6.922

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Diffusion of tetracycline across the outer membrane of Escherichia coli K-12: involvement of protein Ia.

Authors:  I Chopra; S J Eccles
Journal:  Biochem Biophys Res Commun       Date:  1978-07-28       Impact factor: 3.575

2.  Isolation of outer membrane proteins of Escherchia coli and their characterization on polyacrylamide gel.

Authors:  J Uemura; S Mizushima
Journal:  Biochim Biophys Acta       Date:  1975-12-01

3.  Mode of incomplete cross-resistance among pipemidic, piromidic, and nalidixic acids.

Authors:  S Inoue; T Ohue; J Yamagishi; S Nakamura; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

4.  Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies.

Authors:  M W Hane; T H Wood
Journal:  J Bacteriol       Date:  1969-07       Impact factor: 3.490

5.  Outer membrane proteins of Escherichia coli. VII. Evidence that bacteriophage-directed protein 2 functions as a pore.

Authors:  A P Pugsley; C A Schnaitman
Journal:  J Bacteriol       Date:  1978-03       Impact factor: 3.490

6.  New major outer membrane proteins found in an Escherichia coli tolF mutant resistant to bacteriophage TuIb.

Authors:  J Foulds; T J Chai
Journal:  J Bacteriol       Date:  1978-03       Impact factor: 3.490

7.  Role of porin proteins OmpF and OmpC in the permeation of beta-lactams.

Authors:  A Jaffe; Y A Chabbert; O Semonin
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

8.  In vitro and in vivo activity of DL-8280, a new oxazine derivative.

Authors:  K Sato; Y Matsuura; M Inoue; T Une; Y Osada; H Ogawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

9.  Purification of Citrobacter freundii DNA gyrase and inhibition by quinolones.

Authors:  H Aoyama; K Sato; T Fujii; K Fujimaki; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

10.  Outer membrane permeation of beta-lactam antibiotics in Escherichia coli, Proteus mirabilis, and Enterobacter cloacae.

Authors:  T Sawai; R Hiruma; N Kawana; M Kaneko; F Taniyasu; A Inami
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191
View more
  14 in total

1.  Cloning and expression of the norA gene for fluoroquinolone resistance in Staphylococcus aureus.

Authors:  K Ubukata; N Itoh-Yamashita; M Konno
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

Review 2.  The future of the quinolones.

Authors:  V T Andriole
Journal:  Drugs       Date:  1993       Impact factor: 9.546

3.  Molecular characterization of an Enterobacter cloacae gene (romA) which pleiotropically inhibits the expression of Escherichia coli outer membrane proteins.

Authors:  T Komatsu; M Ohta; N Kido; Y Arakawa; H Ito; T Mizuno; N Kato
Journal:  J Bacteriol       Date:  1990-07       Impact factor: 3.490

4.  Carbapenem resistance in a clinical isolate of Citrobacter freundii.

Authors:  J L Mainardi; P Mugnier; A Coutrot; A Buu-Hoï; E Collatz; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

Review 5.  The future of the quinolones.

Authors:  V T Andriole
Journal:  Drugs       Date:  1999       Impact factor: 9.546

6.  Contribution of permeability and sensitivity to inhibition of DNA synthesis in determining susceptibilities of Escherichia coli, Pseudomonas aeruginosa, and Alcaligenes faecalis to ciprofloxacin.

Authors:  J Bedard; S Chamberland; S Wong; T Schollaardt; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

7.  Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.

Authors:  W V Kern; E Andriof; M Oethinger; P Kern; J Hacker; R Marre
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 8.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 9.  Impermeability to quinolones in gram-positive and gram-negative bacteria.

Authors:  L E Bryan; J Bedard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

10.  Reduced susceptibilities of Shigella sonnei strains isolated from patients with dysentery to fluoroquinolones.

Authors:  S Horiuchi; Y Inagaki; N Yamamoto; N Okamura; Y Imagawa; R Nakaya
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.